Long-term results of protocol kidney biopsy directing steroid withdrawal in simultaneous pancreas-kidney transplant patients

Nemin Zhu  
*Western University*

Neal E. Rowe  
*University of Ottawa*

Paul R. Martin  
*Western University*

Sean S. Luke  
*Western University*

Thomas B. McGregor  
*Queen's University - Kingston, Ontario*

*See next page for additional authors*

Follow this and additional works at: [https://ir.lib.uwo.ca/anatomypub](https://ir.lib.uwo.ca/anatomypub)

Part of the *Anatomy Commons, and the Cell and Developmental Biology Commons*

**Citation of this paper:**  
Zhu, Nemin; Rowe, Neal E.; Martin, Paul R.; Luke, Sean S.; McGregor, Thomas B.; Myslik, Frank; McAlister, Vivian C.; Sener, Alp; and Luke, Patrick P., "Long-term results of protocol kidney biopsy directing steroid withdrawal in simultaneous pancreas-kidney transplant patients" (2018). *Anatomy and Cell Biology Publications*. 325.  
[https://ir.lib.uwo.ca/anatomypub/325](https://ir.lib.uwo.ca/anatomypub/325)
Long-term results of protocol kidney biopsy directing steroid withdrawal in simultaneous pancreas-kidney transplant patients

Nemin Zhu, MD1; Neal E. Rowe, MD2; Paul R. Martin, MD1,3; Sean S. Luke, MD1; Thomas B. McGregor, MD4; Frank Myslik, MD1; Vivian C. McAlister, MD1,3,5; Alp Sener, MD1,3,5; Patrick P. Luke, MD1,3,5

1Western University Schulich School of Medicine and Dentistry, London, ON; 2Department of Surgery, University of Ottawa, Ottawa, ON; 3Department of Surgery, London Health Sciences Centre, Western University, London, ON; 4Department of Surgery, Queen’s University, Kingston, ON; 5Multi-Organ Transplant Program, London Health Sciences Centre, London, ON, Canada

Cite as: Can Urol Assoc J 2018;12(6):188-92. http://dx.doi.org/10.5489/cuaj.4702

Published online February 23, 2018

Abstract

Introduction: We sought to determine whether protocol biopsies could be used to guide treatment and improve outcomes in simultaneous pancreas-kidney (SPK) patients.

Methods: Between 2004 and 2013, protocol biopsies were performed on SPK patients at 3–6 months and one year post-transplant. Maintenance immunosuppression consisted of a calcineurin inhibitor, anti-proliferative agent, and corticosteroid. Corticosteroid was withdrawn in negative early biopsies, maintained in subclinical/borderline biopsies, and increased if Banff IB or greater rejection was identified. Endpoints included presence of interstitial fibrosis and tubular atrophy on biopsy at one year (IF/TA), rejection episodes, and renal and pancreas function at five years’ followup.

Results: Forty-one SPK transplant patients were reviewed and a total of 75 protocol biopsies were identified. On early biopsy, 51% had negative biopsies, 44% had borderline rejection, and 5% had subclinical rejection. Renal and pancreas function were not significantly different at one, two, and five years post-transplant between negative vs. borderline early biopsy patients. No difference in the degree of IF/TA was found between these two groups.

Conclusions: To our knowledge, this is the first study to evaluate protocol biopsies as an investigative tool prior to steroid withdrawal in SPK patients. Our study suggests that there are no detrimental functional or histological effects at five years post-transplant, despite weaning steroids in the negative biopsy group.

Introduction

Interstitial fibrosis and tubular atrophy (IF/TA) is the principle cause of kidney allograft failure and is commonly precipitated by episodes of acute rejection.1 While recent improvements in immunosuppressive therapy have reduced the incidence of acute rejection, these pharmacological advances have not translated into a reduction in the prevalence of IF/TA or an improvement in long-term outcomes.2,3 Current literature suggests that clinically undetectable graft pathology (including borderline and subclinical rejection) may be a predictor of future development of IF/TA and eventual graft loss.3,5

Subclinical rejection refers to a histological finding of acute cellular rejection using the Banff criteria (≥grade IA) in the absence of renal dysfunction.3,6 Borderline rejection is defined as Banff grade <IA in the absence of renal dysfunction. While some authors consider borderline rejection to be grouped with subclinical rejection, the significance of borderline rejection is largely unknown.3

Protocol biopsies are histological allograft samples taken at predetermined times after transplant, in the absence of any clinically detectable graft dysfunction. These biopsies provide the opportunity to recognize silent graft pathology (subclinical/borderline changes) in a timely manner and potentially optimize treatment to prolong graft function and survival. A study by Nankivell et al demonstrated a high incidence of IF/TA in simultaneous pancreas-kidney (SPK) patients undergoing protocol biopsies.1 However, these biopsies were not used to guide subsequent treatment of patients.

Steroid withdrawal has been controversial in SPK patients, as more antiquated studies suggest that rejection rates and renal function are potentially impacted if steroids are withdrawn in all patients irrespective of rejection risk.7 In our cohort of SPK patients, we aimed to wean corticosteroids in patients with an absence of subclinical or borderline rejection at three months in order to reduce steroid-related complications. The overall aim of this study was to determine whether identification of subclinical pathology with protocol biopsies could be used to select SPK patients for safe steroid withdrawal.
Methods

Patients

The institutional review board approved our study. The study group consisted of 61 consecutive SPK transplant recipients. All recipient surgeries occurred at the London Health Sciences Centre (LHSC) between January 2004 and August 2013. Biopsies were read at LHSC by the pathology department. Patients were followed for a minimum of five years post-transplant. Protocol biopsies were performed on all SPK patients at 3–6 months. Exclusion criteria included: 1) patient declining protocol biopsy (four patients); 2) patient non-compliance (four patients); 3) early graft loss (seven patients); and 4) postoperative anticoagulation therapy (five patients).

Immunotherapy

All SPK patients received anti-thymocyte globulin (total 5–8 mg/kg) for induction immunosuppression and continued on three-drug maintenance immunosuppression (combination of calcineurin inhibitor [tacrolimus], antiproliferative agent [mycophenolate mofetil or sirolimus], and corticosteroid). Target tacrolimus levels were 5–8 ng/ml in the first three months and 3–5 ng/ml thereafter. Methylprednisolone was initiated at 250 mg IV, reduced to 1 mg/kg IV, and reduced daily by 10 mg until oral prednisone was administered at 5 mg daily.

Protocol biopsies

The early 3–6-month protocol biopsy determined the decision to alter corticosteroid therapy. Biopsies were performed under ultrasound guidance with a Monopty biopsy gun (Bard®, Covington GA, U.S.). The biopsy was adequate if a minimum of two full cores with a total of >8 glomeruli were available for assessment under microscopy. If there was no sign of rejection on the biopsy, the prednisone dose was tapered and withdrawn over two weeks. If there was borderline rejection on the biopsy, then prednisone therapy was maintained at 5 mg daily. If Banff IB or greater rejection was identified, patients were treated with methylprednisolone boluses (250 mg then 1 mg/kg the next day, with reductions of 10 mg daily until a dose of 5 mg daily was achieved). Repeat biopsy within nine months was performed to determine presence or absence of rejection or IF/TA.

Protocol biopsies were not performed on the pancreas graft due to technical difficulties in visualizing the pancreas and risk of pancreatitis or bleeding. As well, assessment of post-transplant donor-specific antibodies was not performed in our patients and is currently not part of our post-transplant monitoring protocol.

Outcomes

The outcomes measured included creatinine, estimated glomerular filtration rate (eGFR), presence of IF/TA, number of rejection episodes, and HbA1c.

Statistics

Statistical analysis was carried out using GraphPad Prism 6.0 software (GraphPad Software, Inc. La Jolla, CA, U.S.). T-test was used for the comparison of means and standard deviations of the two groups. Log-rank (Mantel-Cox) test was used to compare graft and patient survival. Analysis was intention to treat based on their initial early protocol biopsy. Differences were considered significant when p<0.05.

Results

Patients and graft survival

Forty-one consecutive SPK transplant patients were reviewed. Donor and recipient characteristics were similar between the steroid withdrawal group (no rejection on protocol biopsy) and the group maintained on steroids (borderline or acute rejection). Demographics are displayed in Tables 1 and 2.

The five-year death-censored renal graft survival rate was 95% in the steroid withdrawal and 100% in the maintenance group (p=NS). The graft losses were secondary to infections and non-compliance. The five-year death-censored pancreas graft survival rates were identical at 85% in each group. Graft losses were secondary to non-compliance and infections, as well as to the development of post-transplant diabetes mellitus from obesity.

Rejection

A total of 41 early protocol biopsies were performed in 41 patients between three and six months. Twenty-six out of 41 patients had one-year followup protocol biopsies that were adequate for analysis; 12 of 41 patients had 16 additional protocol biopsies beyond the followup biopsy. Overall, a total of 85 protocol biopsies were performed. In addition to protocol biopsies, 24 of 41 patients underwent for-cause biopsies for allograft dysfunction at some point during the five years of followup.

Fifty-one percent of patients had no histological changes on early protocol biopsy (negative biopsy group) and prednisone therapy was withdrawn. The one-year protocol biopsy of these patients (n=14) showed that 57% remained negative, 36% developed borderline rejection, and 7% developed Banff IB rejection. Patients who later developed borderline rejection were restarted on steroid therapy. Forty-
four percent of patients had borderline changes on early protocol biopsy (borderline biopsy group) and prednisone therapy was maintained. The one-year protocol biopsy of these patients (n=11) showed that 36% were negative, 55% remained borderline, and 9% developed C4d+/DSA+ subclinical humoral changes (Fig. 1).

Of note, IFTA was quantified using the Banff classification. Grade I represented mild IF/TA and Grade II represented moderate IF/TA. There was only one case of Grade II IF/TA on protocol biopsy. The remaining protocol biopsies were Grade I IF/TA.

There was no difference in the percentage of IF/TA between the negative vs. borderline biopsy groups at one year (56% vs. 50%; p=0.81) or at any protocol biopsy time point (67% vs. 67%; p=1). There was also no difference in the number of clinical rejection episodes in the five years of followup between the two groups (17% vs. 25%; p=0.62).

Two early protocol biopsies (5%) demonstrated subclinical rejection (Banff IA). The first patient received prednisone maintenance successfully, but refused any further protocol biopsy and had excellent renal and pancreatic graft function at five years. The second patient had a biopsy demonstrating Banff IA rejection. He was successfully treated with prednisone bolus therapy. He later developed Banff IIA rejection with C4d+/DSA+ antibody-mediated rejection at 18 months, demonstrated on followup protocol biopsy, despite having excellent graft function (creatinine 105 µmol/L, HbA1c 0.056). He was treated with plasmapheresis/intravenous immunoglobulin 2 g/kg and prednisone therapy, but lost his renal allograft from ongoing rejection four years post-transplant. He remains insulin-independent. One patient in the borderline group had a rising amylase despite having a stable serum creatinine at nine months postoperatively. This patient had a negative renal biopsy, but since the amylase remained elevated, the pancreas was biopsied one week later; this showed no evidence of rejection.

Four patients were excluded from the study because they declined the early protocol biopsy. Three of these patients received a biopsy at one year, which showed borderline changes. One of these patients subsequently developed antibody-mediated rejection at six months. The fourth patient never received any protocol biopsies. He later developed IF/TA, demonstrated on a for-cause biopsy at 11 months.

**Graft function and survival**

The three-month (89 vs. 105 µmol/L; p=0.05) and two-year (90 vs. 105 µmol/L; p=0.04) post-transplant serum creatinine was statistically lower in the negative vs. borderline biopsy group (Table 3). However, the five-year post-transplant serum creatinine was not significantly different between the two groups. More importantly, there was no difference in the eGFR, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation between the two groups at three months (90 vs. 80 ml/min/1.72 m²; p = 0.21), one year (75 vs. 76 ml/min/1.72 m²; p=0.85), two

---

**Table 1. Donor demographics**

| Characteristic | Negative biopsy (steroid withdrawal) | Positive biopsy (steroid maintained) | p   |
|----------------|--------------------------------------|--------------------------------------|-----|
| Age            | 31.8±12.3                            | 29.4±10.7                            | NS  |
| Kidney CIT     | 5.78±2.47                            | 6.96±2.58                            | NS  |
| Pancreas CIT   | 6.47±2.60                            | 8.13±3.06                            | NS  |
| BMI (kg/m²)    | 25.85±2.99                           | 25.6±4.2                             | NS  |

Data are mean ± standard deviation. BMI: body mass index; CIT: cold ischemic time.

---

**Table 2. Recipient demographics**

| Characteristic | Negative biopsy (steroid withdrawal) | Positive biopsy (steroid maintained) | p   |
|----------------|--------------------------------------|--------------------------------------|-----|
| Age            | 43.8±8.70                            | 41.9±9.13                            | NS  |
| Sex (male %)   | 55%                                  | 65%                                  | NS  |
| Race (caucasian %) | 95%                                  | 100%                                 | NS  |
| Transplant number (first %) | 100%                                 | 100%                                 | NS  |
| PRA %          | 0.7±2.8                              | 1.2±3.4                              | NS  |
| Dialysis (% HD) | 60%                                  | 71%                                  | NS  |

Data are mean ± standard deviation. HD: preoperative mode of dialysis = hemodialysis; PRA%: % panel reactive antibody.
years (82 vs. 75 ml/min/1.72 m²; p=0.53), and five years (65 vs. 55 ml/min/1.72 m²; p=0.91) post-transplant. The five-year kidney graft survival was 95% and 100% in the negative and borderline biopsy groups, respectively (p=NS).

In terms of pancreatic transplant function, both groups displayed similar HbA1c levels at three month (0.053 vs. 0.056; p=NS), one year (0.053 vs. 0.058; p=0.05), and five years (0.053 vs. 0.048; p=NS) post-transplant. The percentage of patients who remained insulin-free was the same in both groups at five years (Table 4).

Steroid-related complications

We did not detect a difference in common steroid-related complications, including impaired glucose tolerance, hypertension, and dyslipidemia, between the negative and borderline biopsy groups (Table 5). As well, none of the patients developed avascular necrosis of the hips and four patients in each group had cataract surgeries in the five years following transplantation.

Discussion

In this study, 44% of patients had early protocol biopsies demonstrating borderline rejection and 5% had subclinical rejection. These results are consistent with the findings of Nankivell et al, who demonstrated subclinical rejection (acute and borderline) in 45.7% of patients at three months.1 In addition, our protocol biopsies demonstrated a high percentage of IF/TA at one year. The ability to detect subclinical rejection and IF/TA in kidney-only transplant patients had previously been shown to allow early treatment that may theoretically prolong graft function and survival.6,8 Choi et al demonstrated that subclinical rejection detected at two weeks post-transplant was associated with a 30% decrease in graft survival at 10 years compared to those with normal findings.8 A small, randomized control trial by Rush et al showed that treatment of subclinical rejection detected by protocol biopsies lead to better histological and functional outcomes in renal transplant patients compared to patients with no protocol biopsies.8 Recent findings from Loupy et al showed that there are two distinct phenotypes of subclinical rejection, T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), which are associated with distinct outcomes.9 Specifically, subclinical ABMR detected on one-year protocol biopsy was associated with the poorest graft survival compared to the subclinical TCMR or negative biopsy groups.9 The distinction of subclinical TCMR and ABMR was not within the scope of our study.

The use of corticosteroids is an integral part of immunosuppressive therapy, but is also associated with multiple adverse effects, including bone demineralization, weight gain, impaired glucose tolerance, and heart disease.10 Therefore, steroid withdrawal is a worthwhile goal in the management of SPK patients post-transplant. However, historical publications have indicated that steroid withdrawal may increase rejection and inferior long-term survival in renal transplant recipients.7 In our study, the early protocol biopsy was used to determine whether steroid therapy could be withdrawn in those patients at low risk for subsequent acute/chronic rejection. We assumed that patients with a negative early protocol biopsy represented a “low-risk” population. In these patients, steroid withdrawal did

| Table 3. Renal function and survival for negative and borderline early protocol biopsies |
|------------------------------------------|------------------------------------------|----------|
| Negative (steroid withdrawal) | Positive (steroid maintained) | p |
| Mean Cr 3 months | 89±16 | 105±30 | 0.05 |
| 1 year | 97±17 | 107±20 | 0.04 |
| 2 years | 90±14 | 105±29 | 0.04 |
| 5 years | 92±14 | 113±15 | 0.01 |
| Mean eGFR 3 months | 90±21 | 80±20 | NS |
| 1 year | 75±16 | 76±15 | NS |
| 2 years | 82±22 | 75±18 | NS |
| 5 years | 65±9 | 55±18 | NS |
| 5-years graft survival | 95% | 100% | NS |

Data are means ± standard deviation. Cr: creatinine; eGFR: estimated glomerular filtration rate; NS: non-significant.

| Table 4. Pancreas function and survival for negative and borderline early protocol biopsies |
|------------------------------------------|------------------------------------------|----------|
| Negative (steroid withdrawal) | Borderline (steroid maintained) | p |
| Mean HbA1c 3 months | 0.053±0.009 | 0.056±0.008 | NS |
| 1 year | 0.052±0.005 | 0.058±0.009 | 0.05 |
| 5 years | 0.053±0.006 | 0.048±0.004 | NS |
| 5-year graft survival | 85% | 85% | NS |

Data are means ± standard deviation. Pancreas graft survival is indicated by recipients being insulin-free. HbA1c: hemoglobin A1c; NS: non-significant.

| Table 5. Steroid-related complications for negative and borderline early protocol biopsies |
|------------------------------------------|------------------------------------------|----------|
| Negative (steroid withdrawal) | Positive (steroid maintained) | p |
| LDL pre-transplant (mmol/L) | 1.9±0.5 | 2.1±0.6 | NS |
| LDL 1 year post-transplant | 1.7±0.6 | 2.0±0.6 | NS |
| Blood pressure pre-transplant (mmHg) | 137/77 | 131/72 | NS |
| Blood pressure post-transplant (mmHg) | 128/69 | 130/76 | NS |

LDL: low-density lipoprotein; NS: non-significant.
not lead to increased histopathological changes at one year compared to borderline/subclinical biopsy patients who were maintained on steroids. There was also no difference in the eGFR or HbA1c between the two groups at five years post-transplant. This suggests that there are no functional detrimental effects despite weaning steroids in the negative early biopsy group. Therefore, the early protocol biopsy identified a group in whom steroid therapy could be successfully weaned. Compared with early steroid withdrawal (within one week) in all patients, minimal steroid exposure is not achieved using our approach, which may have limited our ability to reduce all steroid-related complications. Our biopsy approach, therefore, offers a compromise between early withdrawal and steroid maintenance strategies.

Unlike subclinical rejection, in which treatment is generally supported, the clinical benefit of treating borderline rejection is less clear. Roberts et al reported that early biopsy showing borderline changes go on to develop clinical rejection if left untreated. Nankivell et al showed that patients with borderline rejection had subsequent biopsies showing higher grades of chronic rejection. Herein, we did not detect a difference between the negative vs. borderline biopsy groups in the number of patients with IF/TA at one year and the number of clinical rejection episodes at five years post-transplant. This finding suggests that low-dose prednisone may be beneficial in preventing worsening of IF/TA in the borderline rejection group. Greater numbers are needed to determine whether modification of immunotherapy (steroid boluses, increasing immunotherapy dose) of this “at-risk” group will reduce IF/TA and improve long-term graft survival.

In our protocol biopsies, only the kidney transplant is biopsied. Our steroid withdrawal protocol assumes that concordant rejections occur within both kidney and pancreatic allografts. However, it is believed that there may be a significant discordance between renal biopsies and pancreatic allograft biopsies with regards to the detection of rejection. As the clinical impact of protocol biopsies of the pancreas transplant has not been studied, it is unknown whether discordance in subclinical rejections can also occur in pancreas and kidney allografts.

There are a few limitations to this study. First, this was a retrospective chart review and patients were not randomized to steroid withdrawal vs. maintaining steroid therapy in either group. Therefore, the true significance of steroid withdrawal on renal function and histology of biopsy-negative patients is unknown, and potentially, the rates of IF/TA could have been reduced if corticosteroids were not withdrawn on the biopsy-negative group. Importantly, the number of patients included in this study was small, and the impact of steroid withdrawal on steroid-related factors was beyond the scope of the study. These weaknesses were balanced by the long followup of a minimum of five years in our cohorts. We recommend a study using greater patient numbers in order to determine the optimal approach in treating borderline rejection discovered on protocol biopsy in SPK patients.

**Conclusion**

To our knowledge, this is the first study to evaluate the role of protocol biopsies in guiding steroid withdrawal for SPK transplant patients. Our study suggests weaning steroids in the negative early biopsy group does not lead to worse functional or histological pathology at five years post-transplant vs. the borderline group. Further investigations are needed to determine the significance of borderline rejection and whether immunotherapeutic modifications have any impact on IF/TA.

**Competing interests:** Dr. Martin has been an advisor for Janssen and has received speaker honoraria from Astellas, Paladyn, and Pfizer. Dr. Sener has received grants/honoraria from CONNAED, Eli Lilly, and FirstKIND; and is the co-founder of Clearwater Clinical Limited. The remaining authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

**References**

1. Nankivell B, Barlow R, Fung C, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33. https://doi.org/10.1056/NEJMoa020009

2. Rush D. Protocol transplant biopsies: An underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006;1:138-43. https://doi.org/10.2215/CJN.00390705

3. Glor J, Cohen A, Leger D, et al. Subclinical rejection in tacrolimus treated renal transplant recipients. Transplantation 2002;73:1965-7. https://doi.org/10.1097/00007890-200206270-00023

4. Rush D. Protocol biopsies should be part of the routine management of kidney transplant recipients. Am J Kidney Dis 2002;40:671-3. https://doi.org/10.1053/ajkd.2002.36427

5. Kue T, Chapman J, O’Connell P, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006;82:36-42. https://doi.org/10.1097/01.tp.0000225783.86950.02

6. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998;9:2129-34.

7. Sinclair N. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. CMAJ 1992;147:645-7.

8. Choi B, Shin M, Shin S, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single centre. Am J Transplant 2005;5:1354-60. https://doi.org/10.1111/j.1600-6143.2005.00830.x

9. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015;26:1721-31. https://doi.org/10.1681/ASN.2014040399

10. Maghadem-Kao S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:239-48. https://doi.org/10.1111/j.1365-4632.2009.04322.x

11. Roberts J, Reddy S, Russell C, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens offered renal transplantation. Transplantation 2004;77:1194-8. https://doi.org/10.1097/01.TP.0b013e318216dd17e

12. Trowsell ML, Koslin DB, Norman D. Pancreatic allograft rejection: analysis of concurrent renal allograft biopsies and post-transplant followup biopsies. Transplantation 2010;90:75-84. https://doi.org/10.1097/TP.0b013e3181dd17e

**Correspondence:** Dr. Patrick P. Luke, Department of Surgery, Division of Urology, Western University, London, ON, Canada; patrick.luke@lhsc.on.ca